Balaxi Pharmaceuticals Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Balaxi Pharmaceuticals Ltd is ₹ 24.88 as of 18 May 09:29 . The P/E Ratio of Balaxi Pharmaceuticals Ltd changed from 14.1 on March 2025 to 11.8 on March 2023 . This represents a CAGR of -4.35% over 4 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Balaxi Pharmaceuticals Ltd changed from ₹ 2702 crore on March 2024 to ₹ 2699 crore on March 2023 . This represents a CAGR of -0.02% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Balaxi Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 72.64 crore. This represent the decline of -100% The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The ebitda of Balaxi Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 3.19 crore. This represent the decline of -100% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The net profit of Balaxi Pharmaceuticals Ltd changed from ₹ 6.48 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The Dividend Payout of Balaxi Pharmaceuticals Ltd changed from 3.41 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited was initially incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942.
The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021.
Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading.
The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Balaxi Pharmaceuticals Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Balaxi Pharmaceuticals Ltd or Sanjivani Paranteral Ltd?

Market cap of Balaxi Pharmaceuticals Ltd is 142 Cr while Market cap of Sanjivani Paranteral Ltd is 167 Cr

What are the key factors driving the stock performance of Balaxi Pharmaceuticals Ltd and Sanjivani Paranteral Ltd?

The stock performance of Balaxi Pharmaceuticals Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Balaxi Pharmaceuticals Ltd and Sanjivani Paranteral Ltd?

As of May 18, 2026, the Balaxi Pharmaceuticals Ltd stock price is INR ₹25.88. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹136.3.

How do dividend payouts of Balaxi Pharmaceuticals Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Balaxi Pharmaceuticals Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.